NEO

ANALYST NOTE: NEO (NeoGenomics, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

As of the close on 2026-06-13, NEO presents a confirmed coil setup. The breakout signal has fired, and the stock is currently trading at $14.25. The conservative entry level for this confirmed breakout is $14.17. The current price represents an extension of +0.6% above the conservative entry threshold.

The structural quality at the breakout is characterized by a high ATR of 4.9%, which sits within the historical "high" (4–6%) sweet spot for structural integrity. Current volatility remains elevated with an ATR of 4.7%, providing appropriate sizing context for the position. The setup is not merely forming; it is actionable. There is no evidence of a setup being invalidated or a level being violated; the structure is active and positive.

2. The Thesis Layer

The primary secular thesis driving this setup is Biotech & GLP-1 → Diagnostics, where NEO holds a direct and high-confidence beneficiary status. The company is not a peripheral player but a core infrastructure provider for the oncology diagnostic ecosystem.

While the setup is anchored in the direct diagnostics theme, the business model also exposes the company to broader secular tailwinds in Pharma Services (supporting oncology drug discovery and commercialization) and Digital Pathology. The convergence of these themes creates a multi-layered exposure: the immediate demand for molecular testing (NGS) driven by clinical adoption, supported by the long-term growth of the pharmaceutical R&D pipeline. The "Margin Inflector" archetype suggests that as the mix shifts toward higher-value NGS and RaDaR ST products, the underlying economics of the business are improving, reinforcing the conviction in the primary thesis.

3. The Business

NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom, providing oncology diagnostic testing, consultative services, and technical laboratory services. The company serves a diverse client base including community-based pathology and oncology practices, hospital labs, reference labs, academic centers, and pharmaceutical companies.

Key Operational Metrics (as of Q1 2026):

• Revenue Growth: Q1 2026 revenue was $186.7 million, representing an 11% year-over-year increase, exceeding management's guidance.
• Guidance Revision: Following this beat, management raised full-year revenue guidance to a range of $797 million to $803 million, up from the previous range of $793 million to $801 million.
• Product Mix Shift: The company is successfully transitioning its revenue mix. Five NGS products launched in 2023 now contribute 25% of clinical revenue. Consequently, the NGS business represents approximately one-third (1/3) of total clinical revenue.
• Commercial Execution: The company is expanding its sales force, planning to add roughly 25 sales resources by Q3 2026 to support the penetration of its new RaDaR ST test in two new indications submitted to MolDX.
• Cross-Selling: There is strong evidence of product stickiness; 34% of RaDaR ST orders include additional NEO tests, and 29% of customers who previously used RaDaR 1.0 have migrated to RaDaR ST.

The company operates through two distinct divisions: Clinical Services and Pharma Services. As of December 31, 2025, the company employed approximately 2,500 full-time equivalent employees, including contracted pathologists, with a specialized team of 135 MDs and PhDs serving as a key differentiator.

4. The Archetype and Conviction

NEO fits the Margin Inflector archetype. The evidence suggests a structural improvement in the quality of earnings as the company scales its higher-margin NGS and specialized molecular testing (RaDaR ST) relative to lower-margin traditional services.

• Margin Context: Gross profit margin for Q1 2026 was 43.3%, a slight compression from 43.6% in the prior year period. However, management explicitly stated that R&D expenditures are expected to increase to support innovation and new test launches. This suggests the current margin level is a result of strategic investment rather than operational inefficiency.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.18 for FY1 and $0.36 for FY2.
• Conviction Stack:
• Thesis Strength: High. Direct exposure to the growing oncology diagnostics market.
• Evidence Quality: Strong. Q1 beat, raised guidance, and clear product adoption metrics (RaDaR ST migration).
• Structural Quality: High. The ATR at breakout (4.9%) indicates a robust move with significant volatility support, typical of high-quality breakouts.
• Rerating Potential: Moderate to High. The shift in revenue mix toward NGS (now 1/3 of clinical revenue) and the expansion into new indications (RaDaR ST) provide a narrative for multiple expansion if margins stabilize post-investment.

The combination of a confirmed coil breakout, high ATR structural quality, and a clear path to margin improvement via product mix shifts creates a compelling setup. The recent announcement of a $275 million convertible senior notes offering (announced June 16, 2026, per news feed) is a capital structure event that management has priced; the market's reaction (neutral to positive in the news feed) suggests the capital is viewed as a tool for growth rather than a distress signal.

5. Invalidations, Strengtheners, and Gaps

• What Would Strengthen: Continued acceleration in RaDaR ST adoption rates beyond the current 29% migration; successful MolDX reimbursement decisions for the new indications; stabilization or expansion of gross margins as the R&D investment cycle matures.
• What Would Invalidate: A significant miss on the raised full-year guidance; a sharp decline in gross margins that cannot be attributed to temporary R&D spend; or a failure to secure reimbursement for the new RaDaR ST indications, which would cap the addressable market.
• Gaps in Evidence:
• Reimbursement Specifics: While MolDX submissions are mentioned, specific reimbursement rates or timelines for the new indications are not detailed in the provided evidence.
• Capex Utilization: The specific allocation of the $275 million convertible notes is not broken down in the provided news snippets, leaving the exact deployment strategy (e.g., M&A vs. organic expansion) slightly opaque.
• Pharma Services Growth: While the division exists, specific growth rates for the Pharma Services segment are not quantified in the Q1 transcript evidence provided.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Q1 revenue beat with 11% YoY growth and raised full-year guidance; NGS business now represents 1/3 of clinical revenue with strong RaDaR ST cross-sell metrics; confirmed coil breakout with high structural ATR (4.9%). Key risks: Gross margin compression due to increased R&D spend; execution risk on new sales force hiring and MolDX reimbursement timelines; dilution or market perception regarding the $275M convertible note offering. Rating boundary: This is rated Buy rather than Strong Buy because the gross margin compression (43.3% vs 43.6%) and the recent large capital raise introduce a layer of near-term execution and dilution risk that prevents a top-tier conviction. It would drop to Speculative if the raised guidance is missed or if the new indications face significant reimbursement hurdles. Sizing hint: Position size should reflect the high ATR volatility; standard sizing for a confirmed breakout with high structural quality, adjusted for the recent capital raise. Expected path: Management expects continued revenue growth driven by the 25 new sales hires and RaDaR ST penetration; the company anticipates R&D spend to rise as it brings new tests to market, with the goal of long-term margin inflection as the higher-value NGS mix scales. Expected horizon: 6 to 12 months for the thesis on product mix and margin inflection to fully materialize. Failure mode to watch: A miss on the full-year revenue guidance of $797M-$803M, which would signal a failure in the execution of the raised guidance and the new sales strategy.